ABC | Volume 110, Nº4, April 2018

Original Article Nascimento et al Vimentin and Anti Vimentin Antibodies in Chagas’ Disease Arq Bras Cardiol. 2018; 110(4):348-353 Figure 2 – Sera reactivity profile of patients with different clinical forms of Chagas disease by ELISA with T. cruzi TESA antigens (A) and commercial vimentin (B). Groups were compare with ANOVA with Bonferronipost tests. 3.0 2.5 2.0 1.5 1.0 0.5 0.0 2.5 2.0 1.5 1.0 0.5 0.0 TESAELISA (492nm) Vimentin ELISA (492nm) A B p < 0.001 p < 0.001 p < 0.001 p > 0.05 acute asymptomatic digestive cardiac controls acute asymptomatic digestive cardiac controls Table 1 – Percentage of positivity of sera with different clinical forms of Chagas disease for Vimentin antigen in the ELISA reaction Clinical form Samples (n) Positives (n) Negatives (n) Positivity (%) 95% C.I. (p vs w/o Chagas) p VS undetermined Acute 26 20 6 76.9 53-87 (p < 0.001) p < 0.001 Cardiac 33 29 4 87.8 67-93 (p < 0.001) p < 0.001 Digestive 17 12 5 25 42-84 (p < 0.001) p < 0.01 Symptomatic 76 61 15 80,2 70-88 (p < 0.001) p < 0.001 Undetermined 20 5 15 70,5 5-44 (p < 0.05) Total Chagas 96 66 30 68,5 52-75 (p < 0.001) Without Chagas 40 1 39 2,5 1-4% *Fisher exact test 351